Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

NCT05700669 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer
Recurrent Epithelial Ovarian Cancer
Breast Cancer

Interventions

DRUG: AsiDNA
DRUG: Olaparib

Sponsor

Valerio Therapeutics